JP2019513013A5 - - Google Patents

Download PDF

Info

Publication number
JP2019513013A5
JP2019513013A5 JP2018547926A JP2018547926A JP2019513013A5 JP 2019513013 A5 JP2019513013 A5 JP 2019513013A5 JP 2018547926 A JP2018547926 A JP 2018547926A JP 2018547926 A JP2018547926 A JP 2018547926A JP 2019513013 A5 JP2019513013 A5 JP 2019513013A5
Authority
JP
Japan
Prior art keywords
acid sequence
seq
amino acid
fragment
isolated antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018547926A
Other languages
English (en)
Japanese (ja)
Other versions
JP7157981B2 (ja
JP2019513013A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/021203 external-priority patent/WO2017156032A1/en
Publication of JP2019513013A publication Critical patent/JP2019513013A/ja
Publication of JP2019513013A5 publication Critical patent/JP2019513013A5/ja
Application granted granted Critical
Publication of JP7157981B2 publication Critical patent/JP7157981B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018547926A 2016-03-07 2017-03-07 抗ヌクレオリン抗体 Expired - Fee Related JP7157981B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662304742P 2016-03-07 2016-03-07
US62/304,742 2016-03-07
US201662323159P 2016-04-15 2016-04-15
US62/323,159 2016-04-15
US201662414316P 2016-10-28 2016-10-28
US62/414,316 2016-10-28
PCT/US2017/021203 WO2017156032A1 (en) 2016-03-07 2017-03-07 Anti-nucleolin antibodies

Publications (3)

Publication Number Publication Date
JP2019513013A JP2019513013A (ja) 2019-05-23
JP2019513013A5 true JP2019513013A5 (enExample) 2020-04-16
JP7157981B2 JP7157981B2 (ja) 2022-10-21

Family

ID=59790811

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018547926A Expired - Fee Related JP7157981B2 (ja) 2016-03-07 2017-03-07 抗ヌクレオリン抗体

Country Status (5)

Country Link
US (2) US11357849B2 (enExample)
EP (1) EP3426691A4 (enExample)
JP (1) JP7157981B2 (enExample)
CN (1) CN109071669A (enExample)
WO (1) WO2017156032A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
WO2018081652A2 (en) * 2016-10-28 2018-05-03 Nant Holdings Ip, Llc Avatar dendritic cells: the neoantigen natural killer t-cell chemo immuno radiation composition inducing immunogenic cell death
WO2021234550A1 (ko) * 2020-05-19 2021-11-25 애니젠 주식회사 신규 뉴클레오린-결합 펩타이드 및 이의 용도
AU2022276988B2 (en) * 2021-05-18 2025-01-02 Anygen Co., Ltd. Antiviral composition comprising a nucleolin-binding peptide
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025194038A1 (en) * 2024-03-15 2025-09-18 Caris Science, Inc. Antibody compositions and methods for targeting extracellular nucleosome proteins

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
SG88714A1 (en) 1989-11-06 2002-05-21 Cell Genesys Inc Production of proteins using homologous recombination
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
US5489508A (en) 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
JPH07242566A (ja) 1994-03-01 1995-09-19 Kirin Brewery Co Ltd 免疫抑制剤
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US7357928B2 (en) * 2002-04-08 2008-04-15 University Of Louisville Research Foundation, Inc. Method for the diagnosis and prognosis of malignant diseases
WO2009020923A1 (en) 2007-08-03 2009-02-12 Musc Foundation For Research Development Human monoclonal antibodies and methods for producing the same
EP2200652B1 (en) 2007-09-27 2018-03-21 Children's Medical Center Corporation Microbubbles and methods for oxygen delivery
US9260517B2 (en) * 2009-11-17 2016-02-16 Musc Foundation For Research Development Human monoclonal antibodies to human nucleolin
EP2714094B1 (en) * 2011-06-02 2016-02-24 The University of Louisville Research Foundation, Inc. Anti-nucleolin agent-conjugated nanoparticles

Similar Documents

Publication Publication Date Title
JP6728264B2 (ja) 抗ｈｅｒ２抗体及びその結合体
CN107530422B (zh) Cd48抗体和其缀合物
CN107735105B (zh) 抗ntb-a抗体和相关组合物以及方法
AlDeghaither et al. Beyond peptides and mAbs—current status and future perspectives for biotherapeutics with novel constructs
CN106938051B (zh) 靶向于组织因子的抗体-药物偶联物
CN110770256B (zh) 靶向axl的抗体及抗体-药物偶联物及其制备方法和用途
CN100482277C (zh) 加利车霉素衍生物-载体缀合物
JP2024001187A (ja) 乳がんの処置のためのヒト化抗ｌｉｖ１抗体
JP2025023994A (ja) バイパラトピックＦＲ－α抗体及びイムノコンジュゲート
JP7510518B2 (ja) 抗ｃ－Ｍｅｔ抗体薬物複合体及びその応用
JP2009541492A5 (enExample)
US20200054764A1 (en) Medical use of anti-c met antibody-cytotoxic drug conjugate
US20260007763A1 (en) Pegylated antibody hydroxyl-bearing drug conjugate
Li et al. Immunotoxins and cancer therapy
TW201801746A (zh) Cd33抗體藥物結合物與化學治療劑之組合
CN116490213A (zh) 用于治疗癌症的人源化抗liv1抗体
CN105828841A (zh) 抗-efna4抗体-药物缀合物
Gelderman et al. Inhibiting complement regulators in cancer immunotherapy with bispecific mAbs
KR20230079154A (ko) 암 치료를 위한 인간화 항-liv1 항체
CN101277716A (zh) 治疗癌症的抗体
RU2822497C1 (ru) Конъюгат антитело против c-met-лекарственное средство и его применение
CN120774988A (zh) 一种连接子、抗体药物偶联物及其制备方法
HK40121867A (en) Cd47 blocking agent and anti-bcma / anti-cd3 bispecific antibody combination therapy
HK40104403A (en) Neoadjuvant use of antibody-drug conjugates
KR20250051793A (ko) 항-her2 항체-면역 작용제 접합체의 약학적 조성물 및 이의 응용